Literature DB >> 30677457

The Prevalence of Bladder Cancer During Cystoscopy for Asymptomatic Microscopic Hematuria.

Ashley N Gonzalez1, Michael J Lipsky2, Gen Li3, Matthew P Rutman2, Kimberly L Cooper2, David M Weiner2, Gina Badalato2, Guarionex J Decastro2, Sven Wenske2, James M McKiernan2, Christopher B Anderson2.   

Abstract

OBJECTIVE: To investigate the rate of bladder cancer in patients undergoing cystoscopic evaluation for asymptomatic microscopic hematuria (AMH) in order to identify groups at sufficiently low-risk for bladder cancer in whom invasive testing may be avoided.
METHODS: We performed a retrospective review of patients who underwent cystoscopic evaluation for AMH between 2010 and 2018. Age, gender, smoking status, history of pelvic radiation, and number of red blood cells per high-power field on urine microscopy were recorded. We used logistic regression to explore the association between specific risk factors and a diagnosis of bladder cancer on cystoscopy.
RESULTS: Among the 2118 patients who underwent cystoscopy for AMH, 25 patients (1.2%) were diagnosed with a bladder cancer, all of which were nonmuscle invasive urothelial carcinoma. There were no bladder cancers detected in patients under the age of 50. Older age and positive smoking history were significantly associated with bladder cancer.
CONCLUSION: Bladder cancer was an uncommon finding on cystoscopy among patients being evaluated for AMH, especially in younger patients. We confirmed several known risk factors for bladder cancer, including older age and smoking history. Further studies are required to evaluate the utility of cystoscopy for identifying latent bladder cancers in low-risk patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30677457     DOI: 10.1016/j.urology.2019.01.011

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  Clinical Evaluation of Two Non-Invasive Genetic Tests for Detection and Monitoring of Urothelial Carcinoma: Validation of UroVysion and Xpert Bladder Cancer Detection Test.

Authors:  Niko Kavcic; Ivan Peric; Andreja Zagorac; Nadja Kokalj Vokac
Journal:  Front Genet       Date:  2022-06-06       Impact factor: 4.772

2.  Utility of Contemporary Health Screening in the Diagnosis of Bladder Cancer.

Authors:  Chung-Un Lee; Wan Song; Michael Jakun Koo; Youngjun Boo; Jae-Hoon Chung; Minyong Kang; Hyun-Hwan Sung; Hwang-Gyun Jeon; Byong-Chang Jeong; Seong-Il Seo; Hyun-Moo Lee; Jeongyun Jeong; SeongSoo Jeon
Journal:  Diagnostics (Basel)       Date:  2022-04-21

3.  Assessment of Diagnostic Yield of Cystoscopy and Computed Tomographic Urography for Urinary Tract Cancers in Patients Evaluated for Microhematuria: A Systematic Review and Meta-analysis.

Authors:  Sharon Waisbrod; Anastasios Natsos; Marian Severin Wettstein; Karim Saba; Thomas Hermanns; Christian Daniel Fankhauser; Alexander Müller
Journal:  JAMA Netw Open       Date:  2021-05-03

4.  Can Routine Blood and Urine Parameters Reveal Clues to Detect Bladder Cancer? A Case-Control Study.

Authors:  Dan-Qi Wang; Juan Shuai; Hang Zheng; Zhong-Qiang Guo; Qiao Huang; Xiao-Feng Xu; Xiao-Dong Li; Hao Zi; Dao-Jing Ming; Xuan-Yi Ren; Xian-Tao Zeng
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.